2-substituted-4-methoxybenzimidazole-based PDE4 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 19, 1998, Pages 2737-2742

  Regan, John ^a,c   Bruno, Joseph ^a   McGarry, Daniel ^a   Poli, Gregory ^a   Hanney, Barbara ^a   Bower, Shelly ^a   Travis, Jeffrey ^a   Sweeney, Dennis ^a   Miller, Bruce ^a   Souness, John ^a   Djuric, Stevan ^a,b  

^a SANOFI   (France)

^b ABBOTT LABORATORIES   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROLIPRAM;

ARTICLE; BIOAVAILABILITY; CATALYSIS; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME DEGRADATION; INFLAMMATION; NONHUMAN; SECOND MESSENGER;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BENZIMIDAZOLES; KINETICS; MICE; OXIDATION-REDUCTION; PHOSPHODIESTERASE INHIBITORS; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032491238     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00497-1     Document Type: Article

References (26)

1. 1. Beavo, J. A. Physiol. Rev. 1995, 75, 725.
2. 2. Bourne, H. R.; Lichtenstein, L. M.; Melmon, K. L.; Henry, C. S.; Weinstein, Y.; Shearer, G. M. Science 1974, 184, 19.
3. 3. Verghese, M. W.; McConnell, R. T.; Strickland, A. B.; Gooding, R. C.; Stimpson, S. A.; Yarnall, D. P.; Taylor, J. D.; Furdon, P. J. J. Pharmacol. Exp. Ther. 1995, 272, 1313.
4. 4. de Brito, F. B.; Souness, J. E.; Warne, P. J. Emerging Drugs 1997, 2, 249.
5. 5. Marriot, J. B.; Westby, M.; Dalgleish, A. G. Drug Develop. Today 1997, 2, 273.
6. 6. Palfreyman, M. N. Drugs of the Future 1995, 20, 793.
7. 7. Schwabe, U.; Miyake, M.; Ohaga, Y.; Daly, J. W. Mol. Pharmacol. 1976, 12, 900.
8. 8. Reviews: (a) Stafford, J. A.; Feldman, P. L. Ann. Rep. Med. Chem.; Academic: New York, 1996; Chapter 8, pp 71-81.
9. (b) Davidsen, S. K.; Summers, J. B. Exp. Opin. Ther. Patents 1995, 5, 1087.
10. (c) Palfreyman, M. N. and Souness J. E. Prog. Med. Chem. 1996, 33, 1.
11. 9. Ashton, M. J.; Cook, D. C.; Fenton, G.; Karlsson, J-A.; Palfreyman, M. N.; Raeburn, D.; Ratcliffe, A. J.; Souness, J. E.; Thurairatman, S.; Vicker, N. J. Med. Chem. 1994, 37, 1696.
12. 10. (a) Stafford, J. A.; Feldman, P. L.; Marron, B. E.; Schoenen, F. J.; Valvano, N. L.; Unwalla, R. J.; Domanico, P. L.; Brawley, E. S.; Leesnitzer, M. A.; Rose, D. A.; Dougherty, R. W. Bioorg. Med. Chem. Lett. 1994, 4, 1855.
13. (b) For recent patent activity on the replacement of the 3,4-dialkoxyphenyl ring with benzofurans see: Byk Gulden Lomberg: WO 96/03399, 1996 and Chiroscience: WO 97/44337, 1997.
14. (c) For recent reports of other heterocycles as surrogates for the 3,4-dialkoxyphenyl ring see: Hulme, C.; Moriarity, K.; Miller, B.; Mathew, R.; Ramanjulu, M.; Cox, P.; Souness, J.; Page, K. M.; Uhl, J.; Travis, J.; Huang, F-C.; Labaudinere, R.; Djuric, S. W. Bioorg. Med. Chem. Lett. 1998, 8, 1867; Chiroscience: WO 97/44036, 1997; Pfizer: WO 97/42174-Al, 1997 and Rhône-Poulenc Rorer: WO 97/48697, 1997.
15. (c) For recent reports of other heterocycles as surrogates for the 3,4-dialkoxyphenyl ring see: Hulme, C.; Moriarity, K.; Miller, B.; Mathew, R.; Ramanjulu, M.; Cox, P.; Souness, J.; Page, K. M.; Uhl, J.; Travis, J.; Huang, F-C.; Labaudinere, R.; Djuric, S. W. Bioorg. Med. Chem. Lett. 1998, 8, 1867; Chiroscience: WO 97/44036, 1997; Pfizer: WO 97/42174-Al, 1997 and Rhône-Poulenc Rorer: WO 97/48697, 1997.
16. (c) For recent reports of other heterocycles as surrogates for the 3,4-dialkoxyphenyl ring see: Hulme, C.; Moriarity, K.; Miller, B.; Mathew, R.; Ramanjulu, M.; Cox, P.; Souness, J.; Page, K. M.; Uhl, J.; Travis, J.; Huang, F-C.; Labaudinere, R.; Djuric, S. W. Bioorg. Med. Chem. Lett. 1998, 8, 1867; Chiroscience: WO 97/44036, 1997; Pfizer: WO 97/42174-Al, 1997 and Rhône-Poulenc Rorer: WO 97/48697, 1997.
17. 11. Pharmacokinetic studies on 2 have shown that this compound undergoes extensive first pass metabolism in mice resulting in <5% bioavailability. Page, K. M. unpublished results.
18. 12. Grenda, V. J.; Jones, R. E.: Gal, G.; Sletzinger, M. J. Org. Chem. 1965, 30, 259.
19. 13. Sim, T. B.; Yoon, N. M. Synlett. 1994, 827.
20. 50 = 0.5 μM under the same conditions)
21. 15. Schmeichen, R.; Schneider, H. H.; Watchtel, H. Psychopharmacol. 1990, 102, 17.
22. 16. Torphy, T. J.; Stadel, J. M.; Burman, M.; Cieslinski, L. B.; McLaughlin, M. M.; White, J. R.; Livi, G. P. J. Biol Chem. 1992, 267, 1798.
23. 17. (a) Barnette, M. S.; Grous, M.; Ciesliski, L. B.; Burman, M.; Christensen, S. B. Torphy, T. J. J. Pharmacol. Exp. Ther. 1995, 273, 1402.
24. (b) Barnette, M.S.; Bartus, O'L. J.; Burman, M.; Christensen, S. B.; Prabhakar, U.S.; Rush, J. A. Trophy, T. J. Biochem. Pharmacol. 1996, 51, 949.
25. 18. Murine endotoxemia model. Compounds were administered orally in a vehicle of 0.24% methylcellulose/0.2% Tween-20 in water to male, Balb/c mice (20-25 g, Harlan-Sprague Dawley, Inc., Indianapolis, IN) 4 h prior to challenge with LPS (E. coli 055:B5, Sigma Chemical Co., St. Louis, MO, 30 μg/mouse by intraperitoneal injection). Ninety minutes following LPS challenge, mice were anesthetized with Isoflurane and blood was collected by cardiac puncture. The whole blood was allowed to clot on ice and serum was prepared by centrifugation at 500 x g for 10 min. Serum was assayed for TNF-α by ELISA (Genzyme Corp., Cambridge, MA). Dose response curves were generated in duplicate from n = 4-6 mice per dose.
26. 19. Esser, R. E.; Stimpson, S. A.; Cromartie, W. J.; Schwab, J. H. Arthr. Rheum. 1985, 28, 1402.